Abstract:Background: Plasma-based tests to quantify circulating cell-free DNA cancer signal have emerged as viable applications across the cancer continuum, from early detection to optimal disease management. Here we demonstrate the feasibility of a tissue-agnostic, genome-wide methylome enrichment platform based on cell-free methylated DNA immunoprecipitation and high throughput sequencing (cfMEDIP-seq) for cancer detection, cancer signal quantification, and prognostication in head and neck cancer (HNC). Methods: Pre-treatment plasma samples from individuals with newly diagnosed stage I-IV HPV+ or HPV- HNC were analyzed with a bisulfite-free, non-degradative, genome-wide methylome enrichment platform using 5-10 ng of cell-free DNA. For cancer detection, a machine learning classifier used differentially methylated regions to distinguish cancers from non-cancer controls. The area under the receiver operating characteristic curve (AUC) and 95% confidence intervals were calculated. Cancer signals were quantified from average normalized counts across informative methylated regions and a 95% specificity threshold. For prognostication, events were defined as recurrence, progression, or death due to HNC, whichever occurred earliest. Time to event was compared for samples with cancer signal quantities above versus below the threshold. Post-treatment and longitudinal plasma samples from individuals with Stage I-IVB HNC (HPV+ and HPV- included) will be analyzed for recurrence prediction and detection of relapse. More than 100 patients and 300 samples will be analyzed. Results: For cancer detection, 92 pre-treatment plasma samples from HNC cases were distinguished from 674 controls with an AUC of 0.96 (0.94, 0.98). The AUC was 0.93 (0.86, 1.0) for Stage I, 0.93 (0.83, 1.0) for Stage II, 0.96 (0.94, 0.99) for Stage III, and 0.97 (0.96, 0.99) for Stage IV. For prognostication, 91 pre-treatment samples were included (7 stage I, 16 stage II, 23 stage III, 45 stage IV). Median follow-up time was 50.6 months with 27 events. Likelihood of recurrence or progression was significantly higher in samples with cancer signal above the threshold [hazard ratio 5.4 (95% CI 2.25, 12.95), log-rank P<0.001]. In the upcoming analysis, data will be reported on the ability to predict recurrence and relapse in post-treatment samples. Conclusions: The cfMeDIP-seq approach demonstrated robust detection of HNC, across all stages and subtypes, and the ability to predict recurrence and progression from pre-treatment samples. We will report training data with cross validation to predict recurrence and relapse using post-treatment and longitudinal sampling. Collectively, data from these studies indicate that genome wide methylome enrichment has multiple use cases across the care continuum for patients with HNC. Citation Format: Geoffrey Liu, Jun Min, Yarong Wang, Justin Burgener, Ben Brown, Karen Budhraja, Junjun Zhang, Owen Hall, Shu Yi Shen, Martha Pienkowski, Shao Hui Huang, Laurie Ailles, Katrina Rey-McIntyre, Jeremy B. Provance, Eduardo Sosa, Cynthia Frye, Scott Bratman, Brian Allen, Joshua T. Jones, Abel Licon, Jing Zhang, Anne-Renee Hartman, Daniel D. De Carvalho. The development of a tissue-agnostic genome-wide methylome enrichment MRD assay for applications across the cancer care continuum for head and neck malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2427.

Abstract 2610: A High Performance Blood Test for Multiple Cancer Early Screening

Abstract 4601: Toward the development of a $100 screening test for 6 major cancer types

Abstract 2141: Development of a highly-sensitive targeted cell-free DNA epigenomic assay for early-stage multi-cancer screening

Abstract 1266: Development and performance of a multi-cancer early detection test utilizing plasma cfDNA fragmentomics: A large-scale, prospective, multicenter study

Abstract 5150: Multimodal analysis of plasma cell-free DNA methylome for sensitive multi-cancer detection

Abstract 5116: Analytical performance of ELSA-seq, a blood-based test for early detection of multiple cancers

Abstract 5891: Plasma-based BDA-NGS Test Holds Potential in Circulating Nucleic Acid Based Oncogenic Aberration Detection

Abstract 1269: Large-scale validaton studies of a blood-based effective and affordable test for multicancer early detection

Abstract 3330: Development of a genome-wide multiomic atlas of early-stage lung cancer enables identification of novel methylation biomarkers for disease detection beyond TCGA

Abstract 3454: Cell-free DNA methylation and fragmentomic signatures identify tissue damage and predict cancer risk

Abstract 3310: Non-invasive Diagnosis of Colorectal Cancer Via Targeted High-Throughput DNA Methylation Sequencing of Circulating Tumor DNA (Ctdna)

An Ultrasensitive Method for Noninvasive Pan-Cancer Early Detection Based on Targeted Methylation Sequencing of Cell-Free DNA.

Abstract 782: the Genetic and Epigenetic Abnormalities of Plasma Cfdna As Liquid Biopsy Biomarkers to Diagnose Hepatocellular Carcinoma

High-sensitive Multi-Cancers Early Detection for 8 Cancer Types by Cell-Free DNA Targeted Methylation Sequencing: A Retrospective Cohort Study.

Development of a cfDNA based trans-omics approach for early cancer detection

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification

Abstract 2427: The development of a tissue-agnostic genome-wide methylome enrichment MRD assay for applications across the cancer care continuum for head and neck malignancies

Abstract 631: Validation of a panel of methylated DNA and protein markers for multi-cancer detection in plasma

Abstract 3656: Target enrichment of methylated circulating tumor DNA for colorectal cancer detection

Early detection of lung cancer using a panel of circulating cell-free DNA methylation biomarkers.

Abstract 1062: Clinical validation: A blood-based biomarker for early lung cancer detection based on circulating DNA fragmentomics